SYRE vs NGKSY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SYRE · Spyre Therapeutics$103.86 ▲ 7.53%
NGKSY · Niterra (ADR)$7.59 ▲ 7.63%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SYRE +368.3%
- NGKSY +28.5%
Head to head
| Metric | SYRE | NGKSY |
|---|---|---|
| Price | $103.86 | $7.59 |
| Change today | ▲ 7.53% | ▲ 7.63% |
| Market cap | $9.86B | $9.87B |
| Return, 3 months | -1.4% | -23.7% |
| Return, year to date | +217.0% | +8.1% |
| Return, 1 year | +361.2% | +28.5% |
| P/E (TTM) | -37.4 | 8.3 |
| P/B | 10.9 | 1.7 |
| P/E percentile vs own 5y | 2nd | – |
| Dividend yield | – | 2.84% |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +1.4% | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -28.5% | – |
| Analyst target vs. price | +17.5% | – |
| Analyst buy share | 100% | – |
| RSI (14) | 65 | 49 |
| 30-day volatility | 70.7% | 78.1% |
| Max drawdown, 1 year | -27.8% | -38.9% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NGKSY is the largest of the group by market value.
- SYRE has returned the most over the past year.
- SYRE carries the lowest trailing P/E.
- SYRE has been the calmest stock over the last 30 days.